AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.40 -1.88%

-$1.07 today

Market cap
$1.41B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.51M

Average 0.76M

Returns on capital

AnaptysBio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-35.6%

avg -51.5%

ROIC

14.6%

avg -13.3%

ROA

-3.6%

avg -15.0%

Analysis

ROIC is currently the strongest return metric at 14.6% versus its period average of -13.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel R. Faga

President, Chief Executive Officer & DirectorUSD 517.8K46——

Christopher Murphy

Chief Financial OfficerUSD 517.31K42——

John Kwon

Vice President of GI Clinical Development————

Monique Da Silva

Senior Vice President of Corporate Affairs————

Priya Raina

Senior Vice President of Clinical Operations————

Martin Dahl

Senior Vice President of Research————

Benjamin Stone

Chief Business Officer—35——

Cailin Sibley FACR

Senior Vice President of Translational Medicine————

Beth Mueller

Senior Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

42

$9.75M

Net Transaction Value

−$9.75M

Net selling

Most Active

Faga Daniel

13 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 1, 26

RENTON HOLLINGS

Direct

Sell$249.4K
Mar 30, 26

Schmid John P.

Direct

Sell$30K
Mar 30, 26

Schmid John P.

Direct

Sell$426.8K
Mar 30, 26

Schmid John P.

Direct

Sell$701.7K
Mar 27, 26

Faga Daniel

Direct

Sell$202.5K
Mar 27, 26

Faga Daniel

Direct

Sell$28.9K
Mar 27, 26

Faga Daniel

Direct

Sell$148.8K
Mar 27, 26

Faga Daniel

Direct

Sell$214.7K
Mar 27, 26

Faga Daniel

Direct

Sell$29.2K
Mar 27, 26

Faga Daniel

Direct

Sell$33.3K

1–10 of 42

Summary

Insiders reported 0 buys worth $0.00 and 42 sells worth $9.75M over the last 12 months. That adds up to net selling of $9.75M. Faga Daniel was the most active insider with 13 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+183.6%
+11.7% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
+50.9% (5yr)1 analysts

Analysis

Recent growth has been strongest in Revenue at +183.6% over three years. Forward estimates point to EBIT at +50.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does AnaptysBio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ANAB's management, answered from reported figures.

Who manages ANAB?

AnaptysBio, Inc. (ANAB) lists 9 active executives. The top listed executive is John Kwon, Vice President of GI Clinical Development.

Are ANAB insiders buying or selling?

Recent insider activity shows net selling of $8.27M.